CD274 and neoplasm: PD-L1 expression heterogeneity between primary and metastatic tumours as well as dynamic fluctuations at different time points creates uncertainty in relying on tumour tissue expression of PD-L1 for treatment selection, particularly for patients whose tumours harbour EGFR mutations (104, 105).